Press releases
-
-
-
-
-
Internal link ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement
-
Internal link ProQR Prices $75 Million Underwritten Public Offering and Concurrent Private Placement
-
-
Internal link ProQR Highlights Upcoming Presentation at 20th Annual Meeting of the Oligonucleotide Therapeutics Society
-
-
-
Internal link ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit
-
-
-
Internal link ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024
-
Internal link ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting
-
-
-
-
Internal link ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024
-
Internal link ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration
-
Internal link ProQR Announces First Patient Dosed in Phase 1/2 Aurora Trial of QR-1123 for Autosomal Dominant Retinitis Pigmentosa
-
Internal link ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosa
-
Internal link ProQR to Present at Upcoming Scientific Conferences
-
Internal link ProQR to Present at Upcoming Investor Conferences
-